CL2024000063A1 - Biomarcadores para el tratamiento de la enfermedad de alzheimer - Google Patents

Biomarcadores para el tratamiento de la enfermedad de alzheimer

Info

Publication number
CL2024000063A1
CL2024000063A1 CL2024000063A CL2024000063A CL2024000063A1 CL 2024000063 A1 CL2024000063 A1 CL 2024000063A1 CL 2024000063 A CL2024000063 A CL 2024000063A CL 2024000063 A CL2024000063 A CL 2024000063A CL 2024000063 A1 CL2024000063 A1 CL 2024000063A1
Authority
CL
Chile
Prior art keywords
alzheimer
disease
biomarkers
treatment
suspected
Prior art date
Application number
CL2024000063A
Other languages
English (en)
Spanish (es)
Inventor
Swanson Chad
Koyama Akihiko
Kanekiyo Michio
Irizarry Michael
Kramer Lynn
Kaplow June
Verbel David
Dhadda Shobha
Sachdev Pallavi
Reyderman Larisa
Hayato Seiichi
Landry Ishani
Gordon Robert
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2024000063A1 publication Critical patent/CL2024000063A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CL2024000063A 2021-07-09 2024-01-08 Biomarcadores para el tratamiento de la enfermedad de alzheimer CL2024000063A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163220434P 2021-07-09 2021-07-09
US202163203444P 2021-07-22 2021-07-22
US202163263255P 2021-10-29 2021-10-29
US202163263928P 2021-11-11 2021-11-11
US202163264551P 2021-11-24 2021-11-24
US202263306028P 2022-02-02 2022-02-02
US202263269372P 2022-03-15 2022-03-15
US202263364618P 2022-05-12 2022-05-12

Publications (1)

Publication Number Publication Date
CL2024000063A1 true CL2024000063A1 (es) 2024-08-02

Family

ID=83232761

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000063A CL2024000063A1 (es) 2021-07-09 2024-01-08 Biomarcadores para el tratamiento de la enfermedad de alzheimer

Country Status (11)

Country Link
US (1) US20250163135A1 (cg-RX-API-DMAC7.html)
EP (1) EP4367516A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525559A (cg-RX-API-DMAC7.html)
KR (1) KR20240033017A (cg-RX-API-DMAC7.html)
AU (1) AU2022307687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225302A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000063A1 (cg-RX-API-DMAC7.html)
IL (1) IL309468A (cg-RX-API-DMAC7.html)
MX (1) MX2023015183A (cg-RX-API-DMAC7.html)
TW (1) TW202317192A (cg-RX-API-DMAC7.html)
WO (1) WO2023283650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076808A (zh) 2022-09-23 2025-05-30 卫材R&D管理有限公司 减少与神经退行性疾病相关的神经退行性变的方法
WO2025019457A1 (en) * 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025260029A1 (en) 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
PT4121007T (pt) 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
CA3172451A1 (en) * 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Also Published As

Publication number Publication date
WO2023283650A1 (en) 2023-01-12
IL309468A (en) 2024-02-01
JP2024525559A (ja) 2024-07-12
CA3225302A1 (en) 2023-01-12
MX2023015183A (es) 2024-03-14
US20250163135A1 (en) 2025-05-22
EP4367516A1 (en) 2024-05-15
KR20240033017A (ko) 2024-03-12
TW202317192A (zh) 2023-05-01
AU2022307687A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
MX2023015183A (es) Biomarcadores para el tratamiento de la enfermedad de alzheimer.
CL2024002309A1 (es) Métodos de tratamiento usando nivel de p-tau181.
MX2025005880A (es) Metodos de tratamiento que usan un nivel de tomografia de emision de positrones (pet) de tau
CL2020000343A1 (es) Métodos y materiales para evaluar y tratar el cáncer.
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
EA202192260A1 (ru) Биомаркеры циклин-зависимой киназы 2 и их применение
WO2015157407A8 (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
CY1118660T1 (el) Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
MX2020011458A (es) Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio.
Ally et al. Preserved frontal memorial processing for pictures in patients with mild cognitive impairment
ATE512365T1 (de) Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
CR8230A (es) Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado y sondas para diagnostico de ovillos neuro fibrilares yagentes...
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
MX2019009986A (es) Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias.
CL2023001600A1 (es) Biomarcadores del agonista de trem2 y métodos para su uso
BR112022014553A2 (pt) Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic
MX2024013120A (es) Analisis del transcriptoma para el tratamiento de la inflamacion
BR112022004326A2 (pt) Ensaio de base sanguínea para diagnóstico e tratamento com base em fosforilação de tau específica do sítio
CR20230121A (es) Tratamiento de la enfermedad de parkinson
Li et al. Dynamic functional connectivity assesses the progression of Parkinson’s disease
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
EP3850108A4 (en) MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF EARLY-STAGE PARKINSON'S DISEASE AND TREATMENTS
EA202192176A1 (ru) Нарушения, опосредованные интерфероном i типа